



# **HEPATOLOGY**

## **A Textbook of Liver Disease**

**DAVID ZAKIM, M.D.**

Professor of Medicine and Pharmacology  
University of California, San Francisco  
Chief, Liver Studies Unit  
Veterans Administration Hospital  
San Francisco, California

**THOMAS D. BOYER, M.D.**

Assistant Professor of Medicine  
University of California, San Francisco  
Chief, Gastroenterology  
Veterans Administration Hospital  
San Francisco, California

**1982**

**W. B. SAUNDERS COMPANY**

Philadelphia London Toronto Mexico City Rio de Janeiro Sydney Tokyo

**W. B. Saunders Company:** West Washington Square  
Philadelphia, PA 19105

1 St. Anne's Road  
Eastbourne, East Sussex BN21 3UN, England

1 Goldthorne Avenue  
Toronto, Ontario M8Z 5T9, Canada

Apartado 26370—Cedro 512  
Mexico 4, D.F., Mexico

Rua Coronel Cabrita, 8  
Sao Cristovao Caixa Postal 21176  
Rio de Janeiro, Brazil

9 Waltham Street  
Artarmon, N.S.W. 2064, Australia  
Ichibancho, Central Bldg., 22-1 Ichibancho  
Chiyoda-Ku, Tokyo 102, Japan

**Library of Congress Cataloging in Publication Data**

**Main entry under title:**

Hepatology: a textbook of liver disease.

1. Liver—Diseases. I. Zakim, David. II. Boyer, Thomas D. [DNLM: 1. Liver diseases. WI 700 H5292]

RC845.H46 616.3'62 81-50837

ISBN 0-7216-9682-1

AACR2

**Hepatology: A Textbook of Liver Disease**

**ISBN 0-7216-9682-1**

© 1982 by W. B. Saunders Company. Copyright under the Uniform Copyright Convention. Simultaneously published in Canada. All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without written permission from the publisher. Made in the United States of America. Press of W. B. Saunders Company. Library of Congress catalog card number 81-50837.

Last digit is the print number: 9 8 7 6 5 4 3 2 1

# CONTRIBUTORS

**LESLIE Z. BENET, PH.D.**, Chairman, Department of Pharmacy and Professor of Pharmacy and Pharmaceutical Chemistry, University of California, San Francisco.

## *Hepatic Function and Pharmacokinetics*

**MARTIN BLACK, M.B., B.S., F.R.C.P., M.R.C.P.E., D. OBST. R.C.O.G.**, Professor of Medicine and Pharmacology, Temple University School of Medicine. Head, Liver Unit and Director, Section of Clinical Pharmacology, Temple University Medical School. Attending Physician, Temple University Hospital, Philadelphia, Pennsylvania.

## *Hepatic Detoxification of Endogenously Produced Toxins and Their Importance for the Pathogenesis of Hepatic Encephalopathy*

**NORBERT BLANCKAERT, M.D., Ph.D.**, Lecturer, Catholic University of Leuven, Belgium. Research Associate of the National Fund for Scientific Research, Leuven, Belgium.

## *Physiology and Pathophysiology of Bilirubin Metabolism*

**HERBERT L. BONKOWSKY, M.D.**, Associate Professor of Internal Medicine, Dartmouth Medical School, Hanover, New Hampshire. Chief, Division of Digestive Diseases, VA Medical Center, White River Junction, Vermont. Chief, Hepatology Laboratory, Dartmouth-Hitchcock Medical Center, Hanover, New Hampshire.

## *Porphyrin and Heme Metabolism and the Porphyrins*

**KEVIN E. BOVE, A.B., M.D.**, Professor of Pathology and Pediatrics, University of Cincinnati College of Medicine, Ohio. Associate Pathologist, Children's Hospital Medical Center, Cincinnati, Ohio.

## *Reye's Syndrome*

**THOMAS D. BOYER, M.D.**, Assistant Professor of Medicine, University of California, San Francisco. Chief, Gastroenterology, Veterans Administration Hospital, San Francisco, California.

## *Portal Hypertension and Its Complications; Alcoholic Liver Disease*

**LLOYD L. BRANDBORG, M.D.**, Clinical Professor of Medicine, University of California, San Francisco. Staff Physician, VA Medical Center, San Francisco, California.

## *Parasitic Diseases of the Liver; Bacterial and Miscellaneous Infections of the Liver*

**MICHAEL K. CAHALAN, M.D.**, Assistant Professor in Residence, Department of Anesthesia, University of California, San Francisco. Attending Physician, Moffitt Hospital, San Francisco, California.

## *Liver Function and Dysfunction with Anesthesia and Surgery*

**JOSE L. CAMPRA, M.D.**, Lecturer in Internal Medicine, National University of Cordoba, Cordoba, Argentina. Chief, Gastroenterology and Hepatology, Hospital Privado, Cordoba, Argentina.

## *Hepatic Granulomas*

**RALPH R. CAVALIERI, M.D.**, Professor of Medicine, University of California, San Francisco. Chief, Nuclear Medicine, VA Medical Center, San Francisco, California.

## *Interrelationships Between the Thyroid Gland and the Liver*

**JOHN P. CELLO, M.D.**, Assistant Professor of Medicine, University of California, San Francisco. Chief, Gastroenterology, San Francisco General Hospital, California.

## *The Liver in Systemic Conditions*

**ALLEN D. COOPER, M.D.**, Associate Professor of Medicine, Stanford University, Stanford, California.

## *Hepatic Lipoprotein and Cholesterol Metabolism*

**B. DE HEMPTINNE, M.D.**, Department of Surgery, Catholic University of Louvain, Brussels, Belgium.

## *Hepatocyte Growth Factors*

**DAVID EBERLE, M.D.**, Assistant Professor of Medicine, U.C.L.A. School of Medicine, Los Angeles, California. Staff Physician, Wadsworth VA Medical Center, Los Angeles, California.

## *Biochemical Tests for Liver Disease*

**MURRAY EPSTEIN, M.D.**, Professor of Medicine, University of Miami School of Medicine, Florida. Attending Physician, Veterans Administration and Jackson Memorial Hospitals, Miami, Florida.

*Renal Functional Abnormalities in Cirrhosis: Pathophysiology and Management.*

**KENNETH R. FEINGOLD, M.D.**, Assistant Professor of Medicine, University of California, San Francisco, and Veterans Administration Medical Center, San Francisco, California.

*Abnormalities of Glucose Metabolism in Liver Disease*

**SAMUEL W. FRENCH, M.D.**, Professor of Pathology and Vice Chairman, University of California, Davis, School of Medicine. Chief, Laboratory Service, Martinez VA Medical Center, Martinez, California.

*Interpretation of Liver Biopsy and Postmortem Liver*

**LAURENCE A. GAVIN, M.D.**, Assistant Professor of Medicine, University of California Medical Center, San Francisco. Research Associate, VA Medical Center, San Francisco, California.

*Interrelationships Between the Thyroid Gland and the Liver*

**FAYEZ K. GHISHAN, M.D., D.C.H. (London), F.A.A.P.**, Professor of Pediatrics, Division of Gastroenterology-Nutrition, Vanderbilt University School of Medicine. Attending Physician, Vanderbilt Children's Hospital, Nashville, Tennessee.

*Inborn Errors of Metabolism That Lead to Permanent Liver Injury*

**HENRY I. GOLDBERG, M.D.**, Professor of Radiology, University of California, San Francisco.

*Radiologic Evaluation of Disorders of the Liver and Biliary System*

**HOWARD GOLDIN, M.D.**, Associate Clinical Professor of Medicine, Cornell University Medical College, New York, New York. Associate Attending Physician, The New York Hospital, New York, New York.

*Disorders of the Biliary Tract*

**JOHN L. GOLLAN, M.D., PH.D., F.R.A.C.P., M.R.C.P.**, Associate Professor of Medicine, Harvard Medical School, Boston. Associate in Medicine, Brigham and Women's Hospital, Boston, Massachusetts.

*Copper Metabolism, Wilson's Disease, and Hepatic Copper Toxicosis*

**CARL A. GORESKY, M.D.**, Professor of Medicine, McGill University, Montreal, Quebec. Senior Physician, Montreal General Hospital, Quebec.

*Blood-Tissue Exchange and Blood Flow in the Liver*

**NORMAN D. GRACE, M.D.**, Associate Professor of Medicine, Tufts University School of Medicine, Boston, Massachusetts. Chief of Gastroenterology, Faulkner and Lemuel Shattuck Hospitals, Boston, Massachusetts.

*Iron Metabolism and Hemochromatosis*

**HARRY L. GREENE, M.D.**, Professor of Pediatrics, Associate Professor of Biochemistry, and Head, Division of Gastroenterology, Department of Pediatrics; Director, Clinical Nutrition Research Unit, Vanderbilt University School of Medicine, Nashville, Tennessee.

*Inborn Errors of Metabolism That Lead to Permanent Liver Injury*

**JAMES H. GRENDELL, M.D.**, Assistant Professor of Medicine and Physiology, University of California, San Francisco. Attending Physician, San Francisco General Hospital, California.

*Hepatic Transplantation and Resection*

**ROBERT H. HERMAN, M.D.\*** Formerly Associate Clinical Professor of Medicine, University of California School of Medicine, San Francisco. Formerly Chief, Division of Surgery, Letterman Army Institute of Research, San Francisco, California.

*Metabolism of Vitamins by the Liver in Normal and Pathologic Conditions*

**ROBERT S. HILLMAN, M.D.**, Professor of Medicine, University of Washington, Seattle. University Hospital, Seattle, Washington.

*The Liver and Hematopoiesis*

**P. MICHEL HUET, M.D.**, Assistant Professor of Medicine, University of Montreal, Quebec. Senior Physician, Chief, Liver Section, Hôpital Saint Luc, Montreal, Quebec.

*Blood-Tissue Exchange and Blood Flow in the Liver*

**ALBERT L. JONES, M.D.**, Professor of Medicine and Anatomy, University of California, San Francisco. Staff Physician, Medical Service, and Chief of Cell Biology and Aging Section, Veterans Administration Medical Center, San Francisco, California.

*Anatomy of the Normal Liver*

**E. ANTHONY JONES, M.D., F.R.C.P.**, Chief, Liver Diseases Section, DDB, NIADDK, National Institutes of Health, Bethesda, Maryland. Attending Physician, Clinical Center, National Institutes of Health, Bethesda, Maryland.

*Fulminant Hepatic Failure*

\*Deceased.

**NICK KANAS, M.D.**, Assistant Professor of Psychiatry, University of California School of Medicine, San Francisco. Assistant Chief, Psychiatry Service, Veterans Administration Medical Center, San Francisco, California.

#### *Alcoholic Liver Disease*

**NEIL KAPLOWITZ, M.D.**, Professor of Medicine, UCLA School of Medicine, Los Angeles. Chief, Gastroenterology Section, Wadsworth Veterans Administration Hospital, Los Angeles, California.

#### *Biochemical Tests for Liver Disease*

**MICHAEL C. KEW, M.D., PH.D., F.R.C.P.**, Professor of Medicine, University of the Witwatersrand Medical School, Johannesburg, South Africa. Senior Physician, Johannesburg Hospital, Johannesburg. Attending Hepatologist, Baragwanath Hospital, Johannesburg. Director, South African Primary Liver Cancer Research Unit, Johannesburg, South Africa.

#### *Tumors of the Liver*

**K. S. KOCH, PH.D.**, Postgraduate Research Pharmacologist, University of California, San Diego, La Jolla, California.

#### *Hepatocyte Growth Factors*

**O. DHODANAND KOWLESSAR, M.D.**, Professor of Medicine and Director, Division of Gastroenterology, Thomas Jefferson Medical College of Thomas Jefferson University, Philadelphia. Director, Division of Gastroenterology, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.

#### *Hepatic Synthesis and Degradation of Plasma Proteins*

**P. J. LAD, PH.D.**, Assistant Research Pharmacologist, University of California, San Diego, La Jolla, California.

#### *Hepatocyte Growth Factors*

**BENJAMIN H. LANDING, M.D.**, Professor of Pathology and Pediatrics, University of Southern California School of Medicine, Los Angeles. Pathologist-in-Chief and Director of Laboratories, Childrens Hospital of Los Angeles, California.

#### *Cholestatic Syndromes of Infancy and Childhood*

**H. L. LEFFERT, M.D.**, Associate Professor of Medicine, University of California, San Diego, La Jolla, California.

#### *Hepatocyte Growth Factors*

**E. E. LEHMANN, M.D.**, Associate Professor of Medicine, Faculty of Health Sciences, Ben Gurion University of the Negev, Soroka University Hospital, Beer Sheba, Israel.

#### *Laparoscopy*

**IAN L. MACGREGOR, M.D.**, Associate Professor of Medicine, University of Arizona College of Medicine, Tucson. Chief of Gastroenterology, Veterans Administration Hospital, Tucson, Arizona.

#### *Industrial and Environmental Toxins*

**DENNIS MANGANO, PH.D., M.D.**, Assistant Professor in Residence, Department of Anesthesia, University of California, San Francisco. Attending Physician, Veterans Administration and Moffitt Hospitals, San Francisco, California.

#### *Liver Function and Dysfunction with Anesthesia and Surgery*

**JOSE MARTINEZ, M.D.**, Professor of Medicine, Thomas Jefferson University. Senior Member, Cardeza Foundation for Hematologic Research, Philadelphia. Attending Physician, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.

#### *Hemostatic Alterations in Liver Disease*

**CAROLYN KAY MONTGOMERY, M.D.**, Associate Professor in Residence, Department of Anatomic Pathology, University of California School of Medicine, San Francisco. Assistant Chief, Anatomic Pathology Service, VA Medical Center, San Francisco, California.

#### *Alcoholic Liver Disease*

**DAVID H. MOORE, M.D.**, Formerly Fellow in Gastroenterology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania. Active Staff, NPW Hospital, Mercy Hospital, and Nesbitt Memorial Hospital, Wilkes-Barre, Pennsylvania.

#### *Hepatic Synthesis and Degradation of Plasma Proteins*

**ROBERT K. OCKNER, M.D.**, Professor of Medicine, School of Medicine, University of California, San Francisco. Attending Physician, University of California-Moffitt, San Francisco General, and San Francisco Veterans Administration Hospitals. Consultant, Letterman Army Medical Center, San Francisco, California.

#### *Drug-Induced Liver Disease*

**MARIKO OKANIWA, M.D.**, Associate Professor of Pediatrics, Jichi Medical School, Minamikawachi-cho, Tochigi-ken, Japan.

#### *Cholestatic Syndromes of Infancy and Childhood*

**JOSEPH E. PALASKAK, M.D.**, Assistant Professor of Medicine, Department of Internal Medicine, Division of Hematology-Oncology, University of Cincinnati College of Medicine, Ohio. Attending Physician, University of Cincinnati and Consultant, Cincinnati Veterans Administration Medical Center, Ohio.

#### *Hemostatic Alterations in Liver Disease*

## CONTRIBUTORS

**ROBERT L. PETERS, M.D.**, Professor of Pathology, University of Southern California School of Medicine, Los Angeles, California. Chief Pathologist, Rancho Los Amigos Hospital, Downey, California.

*Hepatic Granulomas*

**DONALD A. PIERCE, M.D.**, Fellow in Rheumatology, The University of California at San Francisco. Veterans Administration Hospital, San Francisco, California.

*Immune Mechanisms in the Production of Liver Disease*

**ELLIOT RAPAPORT, M.D.**, William Watt Kerr Professor of Clinical Medicine and Senior Staff Member, Cardiovascular Research Institute, University of California, San Francisco. Chief of Cardiology Service, San Francisco General Hospital Medical Center, California.

*Cardiopulmonary Complications of Liver Disease*

**TELFER B. REYNOLDS, M.D.**, Clayton G. Loosli Professor of Medicine, University of Southern California School of Medicine, Los Angeles. Chief of Hepatology, Los Angeles County-USC Medical Center, Los Angeles, California.

*Hepatic Granulomas*

**WILLIAM S. ROBINSON, M.D.**, Professor of Medicine, Stanford University School of Medicine, Stanford, California.

*Biology of Human Hepatitis Viruses*

**ARNOLD M. ROCHWARGER, M.D.**, Clinical Instructor of Medicine, Cornell University Medical College, New York, New York. Assistant Attending Physician, The New York Hospital, New York, New York.

*Disorders of the Biliary Tract*

**DANIEL F. SCHAFER, M.D.**, Assistant Professor of Medicine, University of Nebraska Medical Center, Omaha. Instructor, Liver Study Unit, Omaha Veterans Administration Hospital, Nebraska.

*Fulminant Hepatic Failure*

**BRUCE F. SCHARSCHMIDT, M.D.**, Associate Professor of Medicine, University of California, San Francisco. Attending Physician, University of California, San Francisco Hospital, and San Francisco General Hospital, California.

*Bile Formation and Cholestasis, Metabolism and Enterohepatic Circulation of Bile Acids, and Gallstone Formation*

**RUDI SCHMID, M.D., PH.D.**, Professor of Medicine, University of California, San Francisco. Director, Liver Center, University of California, San Fran-

cisco. Consulting Physician, Moffitt Hospital, San Francisco VA Hospital, San Francisco General Hospital, and Letterman Army General Hospital, San Francisco, California.

*Physiology and Pathophysiology of Bilirubin Metabolism*

**LEONARD B. SEEFF, M.D.**, Associate Professor of Medicine, Georgetown University School of Medicine, Washington, D.C. Chief, Gastroenterology/Hepatology Section, Veterans Administration Medical Center, Washington, D.C.

*Diagnosis, Therapy, and Prognosis of Viral Hepatitis*

**KAZUO SHIRAKI, M.D.**, Associate Professor of Pediatrics, University of Tokyo, Japan. Professor and Chairman, Department of Pediatrics, Tottori University School of Medicine, Yonago, Tottori, Japan.

*Cholestatic Syndromes of Infancy and Childhood*

**MARVIN D. SIPERSTEIN, M.D., PH.D.**, Professor of Medicine, University of California, San Francisco and Veterans Administration Medical Center, San Francisco. Chief, Metabolism Section, Veterans Administration Medical Center, San Francisco, California.

*Abnormalities of Glucose Metabolism in Liver Disease*

**MARVIN H. SLEISINGER, M.D.**, Professor of Medicine, University of California, San Francisco. Chief, Medical Service-VA Medical Center, San Francisco, California. Professor and Vice-Chairman, Department of Medicine, University of California, San Francisco. Consultant Physician, San Francisco General Hospital, Mount Zion Hospital, Moffitt Hospital, and Letterman Army Hospital, San Francisco, California.

*The Liver in Systemic Conditions*

**EDWARD A. SMUCKLER, M.D., PH.D.**, Professor and Chairman, Pathology Department, University of California, San Francisco School of Medicine. Professor, Pathology, Moffitt Hospital of the University of California School of Medicine, San Francisco, California.

*Patterns of Reaction of the Liver to Injury*

**STEPHEN E. STEINBERG, M.D.**, Assistant Professor of Medicine, University of Minnesota, Minneapolis. Department of Medicine, Hennepin County Medical Center and Division of Hematology, University of Minnesota, Minneapolis.

*The Liver and Hematopoiesis*

**NORMAN TALAL, M.D.**, Professor of Medicine, The University of California at San Francisco. VA Medi-

cal Investigator, Veterans Administration Hospital, San Francisco, California.

*Immune Mechanisms in the Production of Liver Disease*

**RUEDI F. THOENI, M.D.**, Assistant Professor of Radiology, University of California, San Francisco.

*Radiologic Evaluation of Disorders of the Liver and Biliary System*

**BJORN THORBJARNARSON, M.D.**, Clinical Professor of Surgery, Cornell University Medical College, New York, New York. Attending Surgeon, The New York Hospital, New York, New York.

*Disorders of the Biliary Tract*

**MYRON J. TONG, PH.D., M.D.**, Associate Professor of Medicine and Attending Physician, Liver Unit, University of Southern California School of Medicine, Los Angeles. Director, Internal Medicine Residency Program and Chief, Liver Diagnostic Center, Huntington Memorial Hospital, Pasadena, California.

*Chronic Hepatitis*

**DAVID R. TRIGER, M.A., B.M.B.CH., D.PHIL, F.R.C.P.**, Senior Lecturer in Medicine, Sheffield University Medical School, England. Honorary Consultant Physician (Gastroenterology), Royal Hallamshire Hospital, Sheffield, England.

*Evaluation of Liver Disease by Radionuclide Scanning*

**DAVID H. VAN THIEL, M.D.**, Associate Professor of Medicine, Chief of Gastroenterology, University of Pittsburgh School of Medicine, Pennsylvania. Chief of Gastroenterology and Director, Gastroenterology Laboratory, Presbyterian-University Hospital, Pittsburgh, Pennsylvania.

*Disorders of the Hypothalamic-Pituitary-Gonadal Axis in Patients with Liver Disease*

**DONALD A. VESSEY, PH.D.**, Associate Professor of Biochemistry (Medicine) and Pharmacology, University of California, San Francisco, California.

*Hepatic Metabolism of Drugs and Toxins*

**JOHN M. VIERLING, M.D.**, Assistant Professor of Medicine, University of Colorado School of Medicine, Denver. Research Associate, Veterans Administration Medical Center, Denver, Colorado.

*Primary Biliary Cirrhosis; Hepatobiliary Complications of Ulcerative Colitis and Crohn's Disease*

**J. P. VILLENEUVE, M.D.**, Assistant Professor of Medicine, University of Montreal, Quebec. Attending Physician, Liver Section, Hôpital Saint Luc, Montreal, Quebec.

*Blood-Tissue Exchange and Blood Flow in the Liver*

**ROGER L. WILLIAMS, M.D.**, Assistant Professor of Medicine and Pharmacy, University of California School of Medicine, San Francisco.

*Hepatic Function and Pharmacokinetics*

**CAMILLUS L. WITZLEBEN, M.D.**, Professor of Pathology, University of Pennsylvania School of Medicine, Philadelphia. Director of Pathology, Children's Hospital of Philadelphia, Pennsylvania.

*Cystic Diseases of the Liver*

**TADATAKA YAMADA, M.D.**, Assistant Professor of Medicine, U.C.L.A. School of Medicine, Los Angeles, California. Research Associate, VA Wadsworth Medical Center, Los Angeles, California.

*Biochemical Tests for Liver Disease*

**DAVID ZAKIM, M.D.**, Professor of Medicine and Pharmacology, University of California, San Francisco. Chief, Liver Studies Unit, Veterans Administration Hospital, San Francisco, California.

*Metabolism of Glucose and Fatty Acids by the Liver; Alcoholic Liver Disease*

## ACKNOWLEDGMENTS

# PREFACE

The sick patient confronts the physician with two interrelated problems. The physician must discover the organ system causing the illness and then the specific cause for the dysfunction of that organ. Solutions to both of these problems depend on a fundamental knowledge of the pathophysiology of disease, which provides the intellectual framework for thinking logically about clinical problems. The value of a pathophysiologic perspective on illness is not limited, however, to the context of the immediate care of patients. Many of today's concepts relating to the causes and therapies of liver disease will be proved invalid by future research. We expect, however, that the established principles of hepatic physiology and biochemistry will remain constant. These principles, therefore, form the basis for interpreting concepts about disease and for evaluating the validity of research. Moreover, the biochemical and physiologic principles of organ function are the points of departure for advances in our ability to alter the natural course of illness. Thus, we believe that the value of a pathophysiologic approach to disease cannot be overestimated. We have been guided by this idea in organizing the material for this book, in selecting the topics to be discussed, and in choosing the contributors.

The material in the first section of the book is intended to provide the basis for understanding the relationships between hepatic morphology and function and the categories of function that are unique to the liver and have a critical impact on the viability of other organs. The manner in which hepatic disease manifests itself is the overall topic of Section II. Section III deals with methods for evaluating hepatic function *per se*. Etiologic agents in the production of liver disease are discussed in Section IV. The chapters in this portion of the book are organized on the basis of specific disease entities. The approach in all sections is to discuss problems from a pathophysiologic viewpoint. Where possible, this discussion touches on biochemical and molecular mechanisms. Also, we have asked the authors to illuminate not only what is known but in addition, what is unknown and to avoid unrealistic simplifications of complex and controversial issues. When dealing with such issues, we have attempted instead to indicate the level at which there is agreement on basic points.

Since we do not believe it is possible to prepare a definitive text on liver disease, our goal has been to furnish the reader with an up-to-date interim report of progress in this area. In this regard, we believe that this text will serve as a useful source of information for the practicing physician who wants to read in depth about a specific disease or who needs an answer to an immediate clinical problem. It also will be useful for undergraduate medical students who read it primarily for the purpose of acquiring a basic understanding of the presentations and natural histories of diseases and their treatments. Most importantly, we hope that the contents of this book prove to be a stimulus for creative thinking about the unsolved problems of liver dysfunction.

DAVID ZAKIM  
THOMAS D. BOYER

# PREFACE

# ACKNOWLEDGMENTS

We are grateful to our contributors for the efforts they have extended in the preparation of their chapters and for their cooperation in response to our editorial comments. We owe a special word of gratitude to Lynn Vogel, who worked tirelessly as an editorial assistant and typist. Her contribution has been invaluable from the inception of this book. We appreciate the expert help we received from the W. B. Saunders Company, especially from Jack Hanley, Melonia Musser-Brauner, and Sandy Lovegrove. Last, we thank our families for their support during this sometimes trying project.

DAVID ZAKIM

THOMAS A. BOYER

DAVID ZAKIM  
LAWRENCE D. BOYER

## CONTENTS

Chapter 1	ANATOMY OF THE NORMAL LIVER.....	3
	Albert L. Jones	
Gross and Surface Anatomy.....	3	
The Development of the Liver and Gallbladder.....	6	
Structural Concepts of Liver Lobulation....	7	
Inter- and Intralobular Blood-Carrying Vascular Systems and Biliary and Lymphatic Systems.....	8	
Ultrastructure of Hepatic Parenchymal Cells.....	17	
Functional Interpretations Through Structural Analysis.....	22	
Subcellular Alterations During Cholestasis.....	26	
Lipid Metabolism.....	27	
The Extrahepatic Biliary System.....	27	
References.....	30	
Chapter 2	BLOOD-TISSUE EXCHANGE AND BLOOD FLOW IN THE LIVER.....	32
Carl A. Goresky, P. Michel Huet, J. P. Villeneuve		
The Nature of the Blood-Liver Interface ...	32	
Cellular Entry Processes with Mass Conservation.....	38	
Cellular Entry Processes Followed by Metabolic Sequestration or Biliary Secretion.....	45	
The Measurement of Hepatic Blood Flow.....	52	
Chapter 3	HEPATOCYTE GROWTH FACTORS .....	64
H. L. Leffert, K. S. Koch, P. J. Lad, H. Skelly, B. de Hemptinne		
Proliferative Transitions: Terms and Measurement.....	64	
Evidence That Insulin, Glucagon, and EGF Stimulate Hepatocyte Proliferation.....	65	
Chemical Properties of Insulin, Glucagon, and EGF .....	67	
Modes of Proliferogenic Interactions Among Insulin, Glucagon, and EGF with Hepatocytes.....	68	
Proliferogenic Mechanisms of Action of Insulin, Glucagon, and EGF.....	70	
Gaps in Our Current Understanding of Hepatoproliferogens and Their Mechanisms of Action .....	71	
References.....	73	
Chapter 4	METABOLISM OF GLUCOSE AND FATTY ACIDS BY THE LIVER.....	76
David Zakim		
The Nature of Intracellular Metabolism ...	76	
The Central Position of the Liver in the Economy of Metabolism .....	77	
Hepatic Metabolism in the FED State .....	79	

<b>Metabolic Abnormalities in the FED State.....</b>	<b>94</b>
<b>Metabolism During Fasting.....</b>	<b>94</b>
<b>Acquired Disorders of Hepatic Function That Interfere with Metabolism During Fasting.....</b>	<b>103</b>
<b>References.....</b>	<b>106</b>
<b>Chapter 5</b>	
<b>HEPATIC LIPOPROTEIN AND CHOLESTEROL METABOLISM.....</b>	<b>109</b>
<i>Allen D. Cooper</i>	
Serum Lipids and Lipoproteins .....	109
Hepatic Lipoprotein Biosynthesis .....	119
Lipoprotein Degradation by the Liver .....	121
Cholesterol Metabolism by the Liver.....	123
Effects of Liver Diseases on Serum Lipoproteins and Their Metabolism .....	128
References.....	133
<b>Chapter 6</b>	
<b>HEPATIC SYNTHESIS AND DEGRADATION OF PLASMA PROTEINS.....</b>	<b>137</b>
<i>David H. Moore, O. Dhodanand Kowlessar</i>	
Albumin.....	137
Ceruloplasmin.....	141
Haptoglobin.....	142
Alpha-1-Antitrypsin.....	143
Alpha-2-Macroglobulin.....	144
Antithrombin III.....	145
Hemopexin.....	145
Alpha-1 Acid Glycoprotein (Orosomucoid).....	146
C-Reactive Protein.....	146
Alpha-1-Fetoprotein .....	147
Transferrin.....	147
References.....	148
<b>Chapter 7</b>	
<b>METABOLISM OF VITAMINS BY THE LIVER IN NORMAL AND PATHOLOGIC CONDITIONS.....</b>	<b>152</b>
<i>Robert H. Herman</i>	
Metabolism of Vitamins in Normal and Pathologic States.....	154
References.....	189
<b>Chapter 8</b>	
<b>HEPATIC METABOLISM OF DRUGS AND TOXINS.....</b>	<b>197</b>
<i>Donald A. Vessey</i>	
Common Pathways of Xenobiotic Metabolism.....	197
Induction of Drug-Metabolizing Enzymes.....	218
Other Factors Affecting Drug Metabolism.....	220
Metabolically Induced Liver Disease.....	222
Role of the Membrane in Xenobiotic Metabolism.....	227
References.....	227
<b>Chapter 9</b>	
<b>HEPATIC FUNCTION AND PHARMACOKINETICS.....</b>	<b>230</b>
<i>Roger L. Williams, Leslie Z. Benet</i>	
Pharmacokinetic Concepts .....	231
Hepatic Drug Elimination: Physiologic Concepts.....	233
Experimental Studies of Drug Disposition by the Liver.....	238
Predictive Tests .....	243
Pharmacodynamic Observations in Liver Disease .....	244
Conclusions.....	244
References.....	245
<b>Chapter 10</b>	
<b>PHYSIOLOGY AND PATHOPHYSIOLOGY OF BILIRUBIN METABOLISM.....</b>	<b>246</b>
<i>Norbert Blanckaert, Rudi Schmid</i>	
General Aspects.....	247
Mechanistic Aspects of Bilirubin Formation.....	250
Bilirubin Toxicity.....	252
Chemical and Analytic Aspects .....	254
Bilirubin Metabolism: Physiology and Pathophysiology .....	262

Fetal and Perinatal Bilirubin Metabolism.....	282	Chapter 12 PORPHYRIN AND HEME METABOLISM AND THE PORPHYRIAS .....	351
References.....	284	<i>Herbert L. Bonkowsky</i>	
<b>Chapter 11</b>			
<b>BILE FORMATION AND CHOLESTASIS, METABOLISM AND ENTEROHEPATIC CIRCULATION OF BILE ACIDS, AND GALLSTONE FORMATION.....</b>	<b>297</b>	Structures and Properties of Porphyrins ...	352
<i>Bruce F. Scharschmidt</i>		The Heme Biosynthetic Pathway .....	354
Ultrastructure of the Bile Secretory Apparatus.....	297	Utilization and Functions of Hepatic Heme: Hemoproteins.....	357
Formation of Canalicular Bile.....	305	Regulation of Hepatic Heme Metabolism... Porphyrins and Porphyrin Precursors in the Intact Organism.....	359
Role of the Collecting System in Bile Formation.....	318	Classification of the Porphyrias .....	366
Regulation of Bile Secretion.....	320	Erythropoietic Porphyrias.....	367
Cholestasis.....	323	Acute Hepatic Porphyrias.....	368
Enterohepatic Circulation of Bile Acids and Other Biliary Solutes.....	326	Porphyrria Cutanea Tarda (PCT, Chronic Hepatic Porphyria).....	376
Gallstones.....	333	Protoporphyria.....	379
References.....	341	Hepatoerythropoietic Porphyria (HEP).....	383
<b>SECTION II</b>			
<b>MANIFESTATIONS OF DISORDERED LIVER FUNCTION</b>			
<b>Chapter 13</b>			
<b>HEPATIC DETOXIFICATION OF ENDOGENOUSLY PRODUCED TOXINS AND THEIR IMPORTANCE FOR THE PATHOGENESIS OF HEPATIC ENCEPHALOPATHY.....</b>	<b>397</b>	Pathology.....	416
<i>Martin Black</i>		Pathogenesis.....	419
Clinical Manifestations of Effects of Impaired Hepatic Function on the Central Nervous System .....	397	Complications.....	420
Precipitation of Encephalopathy.....	399	Causes of Death.....	426
Clinical Features.....	399	Natural History.....	426
Pathogenesis of Hepatic Encephalopathy...	401	Indices of Severity and Prognosis .....	428
Management.....	407	Diagnosis.....	429
Conclusions.....	410	Management.....	429
References.....	410	Future Trends.....	438
<b>Chapter 14</b>			
<b>FULMINANT HEPATIC FAILURE .....</b>	<b>415</b>	References.....	439
<i>E. Anthony Jones, Daniel F. Schafer</i>		<b>Chapter 15</b>	
Definition.....	415	<b>RENAL FUNCTIONAL ABNORMALITIES IN CIRRHOSIS: PATHOPHYSIOLOGY AND MANAGEMENT.....</b>	446
Classification of Causes.....	415	<i>Murray Epstein</i>	
Renal Sodium Handling.....	447		
Why Ascites Predominates in Liver Disease.....	452		
Renal Water Handling in Cirrhosis.....	453		
Alterations in Potassium Homeostasis .....	454		

Abnormalities of Renal Acidification.....	455	Mechanism of Action of Hormones .....	516
Syndromes of Acute Azotemia.....	455	An Overview of the Hypothalamic-	
Acute Renal Failure (ATN).....	460	Pituitary-Gonadal Axis.....	520
Summary.....	461	Hypothalamic-Pituitary-Gonadal Function	
References.....	462	in Liver Disease.....	522
 		References.....	527
<b>Chapter 16</b>			
<b>PORTAL HYPERTENSION AND ITS COMPLICATIONS.....</b>	<b>464</b>	 	
Bleeding Esophageal Varices, Ascites, and Spontaneous Bacterial Peritonitis		 	
<i>Thomas D. Boyer</i>		 	
Normal Anatomy of the Portal Venous System.....	464	Alcohol and the Heart .....	529
Clinical Features of Portal Hypertension ...	466	Cirrhosis.....	529
Assessment of the Portal Venous System....	470	Acute Infectious Hepatitis.....	535
Pathogenesis of Portal Hypertension.....	474	Hepatoma.....	535
Causes of Portal Hypertension.....	476	References.....	536
Diagnosis and Management of Bleeding Esophageal and Gastric Varices.....	484	 	
Future Developments.....	493	<b>Chapter 20</b>	
References.....	494	<b>CARDIOPULMONARY COMPLICATIONS OF LIVER DISEASE.....</b>	<b>529</b>
 		<i>Elliot Rapaport</i>	
<b>Chapter 17</b>		 	
<b>ABNORMALITIES OF GLUCOSE METABOLISM IN LIVER DISEASE.....</b>	<b>499</b>	Alcohol and the Heart .....	529
<i>Kenneth R. Feingold,</i>		Cirrhosis.....	529
<i>Marvin D. Siperstein</i>		Acute Infectious Hepatitis.....	535
Glucose Intolerance and Liver Disease.....	499	Hepatoma.....	535
Hypoglycemia in Liver Disease .....	504	References.....	536
Hemochromatosis and Glucose Intolerance.....	505	 	
General References.....	506	<b>Chapter 21</b>	
References.....	506	<b>THE LIVER AND HEMATOPOIESIS ..</b>	<b>537</b>
 		<i>Stephen E. Steinberg, Robert S. Hillman</i>	
<b>Chapter 18</b>		 	
<b>INTERRELATIONSHIPS BETWEEN THE THYROID GLAND AND THE LIVER.....</b>	<b>508</b>	Structural Relationships.....	537
<i>Laurence A. Gavin, Ralph R. Cavalieri</i>		Nutritional Requirements and the Enterohepatic Cycle .....	540
Role of the Liver in the Metabolism and Action of Thyroid Hormones .....	509	Hepatocyte Dysfunction and Hematopoiesis.....	543
Thyroid Function in Hepatic Disease .....	512	References.....	545
Hepatic Function in Thyroid Disease .....	513	 	
References.....	514	<b>Chapter 22</b>	
 		<b>HEMOSTATIC ALTERATIONS IN LIVER DISEASE.....</b>	<b>546</b>
<b>Chapter 19</b>		<i>Jose Martinez, Joseph E. Palascak</i>	
<b>DISORDERS OF THE HYPOTHALAMIC PITUITARY-GONADAL AXIS IN PATIENTS WITH LIVER DISEASE.....</b>	<b>516</b>	 	
<i>David H. Van Thiel</i>		Platelets.....	546
		The Coagulation System .....	548
		The Fibrinolytic System.....	553
		Protein Inhibitors of Blood Coagulation ...	555
		Synthesis and Metabolism of Coagulation Proteins.....	556
		Laboratory Tests of Hemostatic Function.....	559
		Platelet Abnormalities in Liver Disease ...	561
		Alterations of the Coagulation System in Liver Disease.....	562
		Alterations of the Fibrinolytic System in Liver Disease.....	567
		Alterations of the Physiologic Inhibitors of Hemostasis in Liver Disease .....	568
		Qualitative Alterations of Plasma Glycoproteins in Liver Disease .....	569
		Therapy of Disordered Hemostasis in Liver Disease .....	570
		References.....	572

## CONTENTS

<b>SECTION III</b>	
<b>EVALUATION OF HEPATIC FUNCTION</b>	
<b>Chapter 23</b>	
<b>BIOCHEMICAL TESTS FOR LIVER DISEASE.....</b>	<b>583</b>
<i>Neil Kaplowitz, David Eberle,     Tadataka Yamada</i>	
Organic Anion Transport.....	584
Hepatic Metabolic Capacity.....	592
Serum Proteins Produced by the Liver.....	596
Serum Markers of Hepatobiliary Disease...	598
Clinical Use of Biochemical Tests.....	605
References.....	607
<b>Chapter 24</b>	
<b>RADIOLOGIC EVALUATION OF DISORDERS OF THE LIVER AND BILIARY SYSTEM.....</b>	<b>612</b>
<i>Ruedi F. Thoeni, Henry I. Goldberg</i>	
Examination of the Liver .....	612
Examination of the Biliary System.....	618
Cholescintigraphy.....	624
Ultrasonography of the Biliary Tree .....	625
Computed Tomography of the Biliary System .....	626
Percutaneous Transhepatic Cholangiography.....	627
Endoscopic Retrograde Cholangiopancreatography .....	628
Therapeutic Use of Radiography.....	629
Percutaneous Transhepatic Biliary Drainage.....	630
References.....	631
<b>Chapter 25</b>	
<b>EVALUATION OF LIVER DISEASE BY RADIONUCLIDE SCANNING .....</b>	<b>633</b>
<i>David R. Triger</i>	
<b>Chapter 26</b>	
<b>INTERPRETATION OF LIVER BIOPSY AND POSTMORTEM LIVER...</b>	<b>646</b>
<i>Samuel W. French</i>	
Method of Examination.....	648
Autopsy of the Liver.....	649
Morphologic Hallmarks of Liver Diseases.....	650
Nonspecific Changes.....	654
References.....	654
<b>Chapter 27</b>	
<b>LAPAROSCOPY.....</b>	<b>671</b>
<i>E. E. Lehmann</i>	
History.....	671
Indications.....	671
Contraindications.....	672
Method.....	673
Complications.....	675
Findings at Laparoscopy .....	676
References.....	677
<b>SECTION IV</b>	
<b>AGENTS THAT PRODUCE LIVER DISEASE</b>	
<b>Chapter 28</b>	
<b>PATTERNS OF REACTION OF THE LIVER TO INJURY.....</b>	<b>681</b>
<i>Edward A. Smuckler</i>	
Cellular Injury.....	683
Cellular Responses to Liver Injury.....	687
Mechanisms of Cellular Injury.....	687
The Formation of Proximate Toxins.....	690
Deletions.....	690
<b>Chapter 29</b>	
<b>DRUG-INDUCED LIVER DISEASE.....</b>	<b>691</b>
<i>Robert K. Ockner</i>	
Clinical Perspectives.....	691
Histologic Patterns of Drug-Induced Liver Injury.....	693

<b>Analgesic, Anti-Inflammatory, and Muscle Relaxant Drugs.....</b>	<b>696</b>	<b>The Histopathology of Alcoholic Liver Disease.....</b>	<b>772</b>
<b>Anesthetic Agents .....</b>	<b>700</b>	<b>An Eclectic Approach to the Treatment of the Chronic Alcoholic .....</b>	<b>774</b>
<b>Anticonvulsants .....</b>	<b>703</b>	<b>References.....</b>	<b>781</b>
<b>Antimicrobials.....</b>	<b>704</b>		
<b>Antituberculous Agents.....</b>	<b>706</b>		
<b>Antineoplastic Agents.....</b>	<b>709</b>		
<b>Drugs Used in the Treatment of Cardiovascular Disease.....</b>	<b>710</b>		
<b>Hormones and Hormonally Active Drugs.....</b>	<b>711</b>		
<b>Psychoactive Drugs.....</b>	<b>714</b>		
<b>References.....</b>	<b>716</b>		
<b>Chapter 32</b>			
<b>IMMUNE MECHANISMS IN THE PRODUCTION OF LIVER DISEASE ...</b>			
<i>Donald A. Pierce, Norman Talal</i>			
<b>Normal Function of the Liver as an Immunologic Organ.....</b>	<b>791</b>		
<b>The Liver As an Immunologic Target .....</b>	<b>792</b>		
<b>Response to Antigen As a Mechanism of Liver Disease.....</b>	<b>792</b>		
<b>Liver Disease As a Manifestation of Other Immune Disorders.....</b>	<b>794</b>		
<b>References.....</b>	<b>795</b>		
<b>Chapter 33</b>			
<b>HEPATOBILIARY COMPLICATIONS OF ULCERATIVE COLITIS AND CROHN'S DISEASE .....</b>			
<i>John M. Vierling</i>			
<b>Overview and Critical Comments .....</b>	<b>797</b>		
<b>Diseases of the Liver.....</b>	<b>798</b>		
<b>Diseases of the Biliary Tract .....</b>	<b>818</b>		
<b>References.....</b>	<b>822</b>		
<b>Chapter 34</b>			
<b>PRIMARY BILIARY CIRRHOSIS .....</b>			
<i>John M. Vierling</i>			
<b>Etiology.....</b>	<b>825</b>		
<b>Incidence and Epidemiology.....</b>	<b>826</b>		
<b>Clinical Features.....</b>	<b>826</b>		
<b>Laboratory Tests.....</b>	<b>828</b>		
<b>Pathology.....</b>	<b>832</b>		
<b>Diseases Associated with PBC .....</b>	<b>839</b>		
<b>Natural History and Prognosis.....</b>	<b>843</b>		
<b>Complications .....</b>	<b>845</b>		
<b>Differential Diagnosis.....</b>	<b>848</b>		
<b>Diagnostic Evaluation.....</b>	<b>849</b>		
<b>Pathogenesis.....</b>	<b>850</b>		
<b>Treatment.....</b>	<b>854</b>		
<b>References.....</b>	<b>858</b>		
<b>Chapter 35</b>			
<b>ALCOHOLIC LIVER DISEASE .....</b>			
<i>David Zakim, Thomas D. Boyer, Carolyn Montgomery, and Nick Kanas</i>			
<b>Relationship Between Ethanol Consumption and the Incidence of Liver Disease.....</b>	<b>739</b>		
<b>Metabolism of Ethanol .....</b>	<b>741</b>		
<b>The Metabolism of Acetaldehyde .....</b>	<b>745</b>		
<b>Metabolic Consequences of Ethanol Ingestion .....</b>	<b>746</b>		
<b>Interaction Between Ethanol and Nutrition .....</b>	<b>759</b>		
<b>Clinical Features of Alcoholic Liver Disease.....</b>	<b>763</b>		

<b>Chapter 35</b>	<b>Chapter 38</b>
<b>BIOLOGY OF HUMAN HEPATITIS VIRUSES.....</b>	<b>HEPATIC GRANULOMAS.....</b>
<i>William S. Robinson</i>	<i>Telfer B. Reynolds, Jose L. Campra, and Robert L. Peters</i>
The Recognition of Hepatitis Viruses in Man.....	Definition and Pathologic Features of Granuloma.....
863	995
The Spectrum of Viruses That Involve the Liver in Man and Other Vertebrates.....	Lipogranulomas .....
864	995
Hepatitis B Virus.....	Implications of Hepatic Granulomas.....
866	997
Hepatitis A Virus.....	Causes of Hepatic Granulomas .....
888	997
The Course of Hepatitis A Virus Infection.....	Clinical Features.....
890	998
Non-A, Non-B Hepatitis Viruses .....	Laboratory Test Abnormalities .....
895	999
References:.....	Differential Diagnosis.....
898	999
Disorders Associated with Hepatic Granulomas.....	1001
References.....	1008
<b>Chapter 36</b>	<b>Chapter 39</b>
<b>DIAGNOSIS, THERAPY, AND PROGNOSIS OF VIRAL HEPATITIS ...</b>	<b>PARASITIC DISEASES OF THE LIVER.....</b>
<i>Leonard B. Seeff</i>	<i>Lloyd L. Brandborg</i>
History .....	Protozoan Infections .....
911	1010
Clinical Features.....	Helminthic Infestations.....
913	1021
Comparative Features of Hepatitis A, Hepatitis B, and Non-A, Non-B Hepatitis.....	References.....
919	1034
Clinical Forms of Expression and Outcomes of Viral Hepatitis.....	<b>Chapter 40</b>
919	<b>BACTERIAL AND MISCELLANEOUS INFECTIONS OF THE LIVER.....</b>
Histopathology of Viral Hepatitis .....	<i>Lloyd L. Brandborg</i>
923	
Light-Microscopic Features of Acute Viral Hepatitis.....	Pyogenic Abscess of the Liver.....
923	1036
Ultrastructural Changes of Acute Viral Hepatitis.....	Hepatic Dysfunction Associated with Systemic Infections.....
927	1039
Light-Microscopic and Electron-microscopic Features of the Chronic Hepatitis B Antigen Carrier.....	Hepatic Dysfunction in Bacterial Sepsis .....
928	1039
Viral Hepatitis and Nonhepatic Disorders.....	Liver Dysfunction in Gram-Positive Infections.....
929	1040
Viral Hepatitis Occurring in Specific Circumstances.....	Liver Dysfunction in Gram-Negative Bacterial Infections.....
936	1042
Treatment of Acute Hepatitis .....	Spirochetal Infections.....
939	1043
Prevention of Viral Hepatitis .....	References.....
942	1046
References.....	
955	
<b>Chapter 37</b>	<b>Chapter 41</b>
<b>CHRONIC HEPATITIS.....</b>	<b>TUMORS OF THE LIVER.....</b>
<i>Myron J. Tong</i>	<i>Michael C. Kew</i>
Chronic Persistent Hepatitis.....	Primary Malignant Tumors .....
972	1048
Chronic Active Hepatitis .....	Benign Liver Tumors.....
974	1072
Chronic Lobular Hepatitis.....	Tumor-Like Lesions .....
987	1077
References.....	References.....
987	1079